title: [Multiple sclerosis and Epstein-Barr virus : new developments and perspectives].
abstract: Data from studies of twins and migrants with multiple sclerosis (MS) imply environmental factors in the development of MS. In this respect, increasing evidence indicates that Epstein-Barr virus (EBV) plays a unique role as an infectious risk factor for MS. A nearly 100% seroprevalence of antibodies to EBV in patients with MS, elevated EBV antibody titers years before clinical onset of the disease, and an increased risk for MS after symptomatic primary EBV infection (infectious mononucleosis) suggest an association of MS with a previous infection with EBV. However, the precise mechanisms through which EBV may contribute to MS are still unclear. Currently discussed potential mechanisms are outlined. The notion of a persisting (possibly immunological) change caused during the acute phase of primary EBV infection and subsequently leading to permanently elevated MS risk appears compatible with several aspects of the association found between MS and EBV.
authors: Institut für Virologie, Haus 47, Universitätsklinikum des Saarlandes, 66421, Homburg/Saar, Deutschland. klemens.ruprecht@uniklinikum-saarland.de
authors: K
authors: K
authors: Ruprecht
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology*; D002648:Child; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007244:Infectious Mononucleosis / Q000453:epidemiology / Q000276:immunology*; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000276:immunology*; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D012897:Slow Virus Diseases / Q000453:epidemiology / Q000276:immunology*; D014774:Virulence
chemical_list: D000914:Antibodies, Viral; D019309:Epstein-Barr Virus Nuclear Antigens
references: Arch Neurol. 2007 Jan;64(1):72-5
references: 17210811
references: Acta Neurol Scand Suppl. 1997;169:8-15
references: 9174635
references: Nat Immunol. 2002 Oct;3(10):940-3
references: 12244309
references: J Immunol. 1999 Jan 1;162(1):129-35
references: 9886378
references: Blood. 2006 Jul 1;108(1):11-8
references: 16543467
references: Arch Neurol. 1980 Feb;37(2):94-6
references: 6243930
references: JAMA. 2006 Dec 20;296(23):2832-8
references: 17179460
references: JAMA. 2003 Jul 9;290(2):192-3; author reply 193
references: 12851269
references: Neurology. 2004 Jun 22;62(12):2277-82
references: 15210894
references: JAMA. 2004 Apr 21;291(15):1875-9
references: 15100207
references: Lancet Neurol. 2005 Mar;4(3):195-202
references: 15721830
references: Trends Immunol. 2003 Nov;24(11):584-8
references: 14596882
references: JAMA. 2005 May 25;293(20):2496-500
references: 15914750
references: Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12877-82
references: 14569025
references: Int MS J. 2006 May;13(2):52-7
references: 16635422
references: Neurology. 2006 Dec 12;67(11):2063-5
references: 17159123
references: Immunity. 2001 Oct;15(4):579-89
references: 11672540
references: Arch Neurol. 2006 Jun;63(6):839-44
references: 16606758
references: Lancet. 1981 Dec 5;2(8258):1290
references: 6118702
references: J Neuroimmunol. 2006 Nov;180(1-2):185-92
references: 17023054
references: Neuroepidemiology. 1992;11(4-6):299-303
references: 1337948
references: JAMA. 2001 Dec 26;286(24):3083-8
references: 11754673
references: J Epidemiol Community Health. 2004 Dec;58(12):1032-5
references: 15547068
references: Rev Med Virol. 2006 Sep-Oct;16(5):297-310
references: 16927411
references: Nat Immunol. 2001 Sep;2(9):802-9
references: 11526390
references: Ann Neurol. 2006 Mar;59(3):499-503
references: 16502434
references: Prog Neurobiol. 1995 Nov-Dec;47(4-5):425-48
references: 8966212
references: Ann Neurol. 2007 Apr;61(4):288-99
references: 17444504